Oct 8, 2024 · 1h 4m · allin
Dave Ricks, CEO of Eli Lilly | The All-In Interview
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this All-In Podcast interview, host David Friedberg speaks with Eli Lilly CEO Dave Ricks about the company's growth, breakthroughs in GLP-1 and incretin therapeutics, and the broader economic, societal, and scientific implications of treating global obesity.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. The hosts hold 35.2% of the talking time here. How this is scored →
The hosts as informed peer 6.2 Guest teaching 3.4 Guest disagreement 0.8 The hosts pushing back 1.4
speaking balance: gold is the hosts, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 1:01:27 Dismissing 'In Silico' AI Drug Discovery Hype
Dave Ricks strongly rejects claims from tech VC-funded biotech startups that drug discovery can be automated entirely in silico, calling their pitch decks naive.
Hardest push from the hosts ▶ 40:16 Challenging 81% Gross Margins and Political CriticismFriedberg directly confronts Ricks on Lilly's 81 percent gross margins and massive profitability, asking how the company justifies its pricing amid political criticism.
Biggest teaching moment ▶ 51:29 Reframing Genetic Medicine toward Scalable siRNARicks redirects Friedberg's focus from boutique cell therapies to siRNA breakthroughs, educating the host on how catalytic knockdown of Lp(a) allows once-a-year treatments for millions.
The host holds their own ▶ 13:26 Explaining GLP-1 L-Cell Biological MechanismFriedberg demonstrates impressive scientific depth by detailing how intestinal L-cells express GLP-1 to signal the brain and pancreas, drawing explicit validation from Ricks.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The hosts as informed peer | Guest teaching | Guest disagreement | The hosts pushing back | Why |
|---|---|---|---|---|---|---|
| Introducing Dave Ricks and Eli Lilly's Financial Growth | 7 | 3 | 1 | 1 | Friedberg opens with detailed epidemiological statistics and chart data regarding calorie consumption and rising obesity rates over 50 years. Ricks accepts the context but gently reframes the data to emphasize the role of ultra-processed foods in the US compared to Europe. | |
| Complications of Obesity and Type 2 Diabetes | 7 | 3 | 0 | 0 | Friedberg displays strong understanding of diabetic comorbidities such as nephropathy and retinopathy as well as recombinant DNA history in E. coli. Ricks provides additional depth on MASH liver disease and Lilly's historic insulin partnership with Genentech. | |
| Biological Mechanism and Development of GLP-1 Agonists | 8 | 4 | 0 | 0 | Friedberg delivers a precise biological explanation of intestinal L-cells and GLP-1 hormone secretion, which Ricks confirms as perfect. Ricks then educates the host on the extended incretin super-family and Gila monster saliva exenatide kinetics. | |
| Peptide Engineering and Multi-Organ Incretin Signaling | 7 | 3 | 0 | 0 | Friedberg breaks down peptide protein structures using an amino acid beaded necklace analogy. Ricks expands on multi-organ metabolic cross-signaling across the liver, heart, and brain. | |
| Clinical Trial Expansion and Preventative Healthcare Challenges | 5 | 4 | 0 | 0 | Ricks outlines Lilly's pipeline of dual and triple incretin agonists along with 105 active clinical trials. Friedberg demonstrates financial grasp by estimating the total trial spend at 10 to 20 billion dollars. | |
| Insurance Coverage, Social Stigma, and LillyDirect | 6 | 3 | 1 | 3 | Friedberg challenges the economic logic of insurers refusing preventative coverage for non-diabetic obesity given long-term actuarial savings. Ricks explains system dynamics including Medicare regulations, social stigma, and LillyDirect's pricing model. | |
| Weight Rebound, Cadence Optimization, and Oral GLP-1s | 6 | 3 | 2 | 5 | Friedberg directly challenges Ricks on whether Lilly has a financial conflict of interest in creating lifetime drug dependency rather than one-time cures. Ricks refutes the framing by outlining research into metabolic setpoint resets and oral GLP-1 molecules. | |
| Food Industry Adaptation and Changing Consumer Behavior | 5 | 2 | 0 | 0 | Friedberg references his personal investment in SuperGut to discuss shifting consumer food habits. Ricks shares grocery cart data from Walmart showing reduced calorie and salty snack purchases. | |
| Eli Lilly's Income Statement, Margins, and U.S. Manufacturing | 7 | 4 | 2 | 6 | Friedberg presses Ricks on Lilly's 81 percent gross margin and high quarterly profits amid political scrutiny over medication costs. Ricks defends the margins by detailing 11 billion dollars in annual R&D spend and PBM rebate dynamics. | |
| Revenue Projections and Long-Term Pipeline Diversification | 6 | 3 | 1 | 2 | Friedberg presents Wall Street operating income projections and questions how Lilly manages patent cliff risks. Ricks outlines the company's four distinct therapeutic divisions to maintain long-term balance. | |
| Emerging Science Modalities: Genetic Medicine and siRNA | 6 | 5 | 0 | 0 | Friedberg asks about futuristic modalities like Yamanaka factors and cell therapies. Ricks re-orients the topic toward siRNA genetic medicine, detailing once-yearly dosing for Lp(a) cardiovascular risk reduction. | |
| M&A Strategy, Organizational Speed, and Corporate Culture | 5 | 3 | 0 | 0 | Friedberg asks about corporate culture and organizational speed at scale. Ricks explains operational changes that reduced drug development timelines from 11 years down to 6.1 years. | |
| AI in Drug Discovery: Co-Pilots vs. Full Automation | 6 | 4 | 3 | 1 | Friedberg asks whether AI drug discovery startups threaten Lilly's long-term business. Ricks forcefully dismisses pitch decks promising total in silico drug discovery as naive, emphasizing necessary wet lab integration. |
Statements from this episode (39)
Analysts project GLP-1 drug market could reach $150B annually within 10 years
“The GLP one drug market, which some analysts have said could grow to as much as a hundred fifty billion in annual revenue over the next 10 years”
Eli Lilly projected to reach $46B revenue and $15B operating income in 2024
“Lilly's market cap is an astounding eight hundred and seventy eight billion dollars, and the company's projected to do forty six billion in revenue and fifteen billion in operating income this year.”
Friedberg: CDC reports 74% of Americans are overweight or obese
“According to the CDC, 74% of Americans are now overweight or clinically obese.”
Friedberg: US daily caloric intake rose from 2,800 to 3,600 since 1961
“The average daily calorie consumed by Americans since 1961 has driven up from 2800 to about 3600.”
Dave Ricks: Two-thirds of US calories are ultra-processed vs 35% in Europe
“In the U S we're now eating two thirds of our calories in our country are ultra processed. And that compares to like 35% in Europe.”
Dave Ricks: India's obesity rate projected to reach 30% within 20 years
“India, I think is 11% of the population's obese, but projected to go as much as 30% in the next 20 years.”
Dave Ricks: 230 diseases are linked to obesity and caloric imbalance
“230 diseases have been connected and you have these pr, these ones that are more like directly because of the caloric imbalance and fat accumulation.”
Epic study links GLP-1 drug use to remarkably lower clinical depression rates
“There's an interesting study done by Epic. You know, they're the big health record company. Which is retrospective and not tightly controlled, but it showed people on GLP-I drugs, incretins, had remarkably lower rates of new clinical depression diagnoses, whic…”
Eli Lilly and Genentech partnered to create the first-ever biotechnology product
“We had partnered with Genentech to do another first, which is create the first biotechnology product on planet earth, which was human insulin made in a bacterial cell.”
Ricks: Native GLP-1 has a half-life of minutes in medicine
“When you give it in its native form as a medicine, it has a half-life of like minutes.”
Ricks: GLP-1 glucose regulation triggers at lower doses than weight loss
“The glucose effect occurs at a lower dose than the weight loss effect.”
Ricks: Novo Nordisk's higher semaglutide dosing enabled obesity treatment
“So it was really Novo's insight that we could push up the dose of semaglutide that allowed the obesity Kind of threshold to be pushed.”
Science does not yet fully understand GLP-1's secondary metabolic effects
“What we don't even fully understand yet though, David, which is interesting is, is that there are primary effects of GLP-I. Certainly we can reproduce like in a test tube or a cell system, but then there's a whole myriad of other probably secondary effects bec…”
Ricks: Eli Lilly's GLP-1 drugs are undefeated in chronic disease trials
“So far in our studies, this category of medicine's undefeated. We've never had an unsuccessful study in measuring an outcome in a chronic disease.”
Ricks: Eli Lilly has 105 active tirzepatide clinical trials
“Currently, Lily has a 105 studies going with trisapatide in these other diseases.”
Ricks: Three-year Mounjaro trial showed 94% reduction in diabetes diagnoses
“We just read that study out with Manjaro, which showed that three years on our drug, 94% fewer new diagnosis of outright diabetes.”
Dave Ricks: Medicare rules prohibit covering weight-loss drugs unless patients have diabetes
“If you're say on Medicare, currently the rule of the federal government is they won't pay. For these medications. You have to get diabetes before you can get the drug.”
Under 5% of obese adults reach healthy weight via lifestyle changes alone
“Some studies show like less than five percent of people can reach a healthy body weight on diet and exercise once they're obese.”
Dave Ricks: About 50% of employer-sponsored health plans cover GLP-1 weight-loss drugs
“Right now about 50% of the employer-sponsored insurance plans cover it.”
Dave Ricks: Employers not covering weight-loss meds will look crazy in five years
“I think in five years we'll look back and we'll say that was crazy. Once the evidence base is built up and there's more adoption and less stigma, but right now that's the current state.”
Eli Lilly oral GLP-1 shows efficacy matching high-dose semaglutide in trials
“In our hands, it, it's about as good as high dose semaglutide, and we, we're doing phase three right now. So that will start to read out next year.”
Ricks: Eli Lilly has regulatory approvals in 40+ unlaunched countries
“We have approvals in more than 40 countries we haven't even launched in.”
Dave Ricks: Walmart study shows GLP-1 users buy 30% fewer calories
“Last year Walmart did this sort of what's in the cart study for people in Ozempic or Manjaro and it showed They were buying about a third less calories. So that's a lot, but that's consistent with how the drugs work. But interesting also, fewer salty snack foo…”
Dave Ricks: 10 to 11 million Americans currently take GLP-1 drugs
“We only have 10 or eleven million Americans on these drugs.”
Eli Lilly CEO expects 2024 R&D spending to exceed $11B
“This year we'll spend over eleven billion dollars on R&D, which is a meaningful it's like a nation state scale.”
Dave Ricks expects steady-state GLP-1 net pricing around $3,000 to $4,000 annually
“Probably net pricing for us, you know, is going to be something like three, 4000 dollars a year in the steady state per person, but I think we'll create more value than that. We'll save the system more money than that per year per user.”
Eli Lilly retains only one-third of gross drug prices after PBM cuts
“Two thirds of actually our gross price goes to PBMs and insurance companies. So of the gross price that's often quoted, the net for us is about a third of that.”
Ricks: Eli Lilly GLP-1 launched at 20% discount to Novo Nordisk
“We launched at a 20% discount to Nova's product, even though we have better efficacy data, and we've only cut the price since then.”
Ricks: Brain and neuroscience diseases cause 40% of global suffering
“About 40% of global suffering is some form of a brain or neuroscience disease.”
Dave Ricks: Eli Lilly gene therapy restored hearing in congenitally deaf children
“We've treated patients that have gone from like six, eight years of life, no hearing at all to now hearing.”
Dave Ricks: CAR-T and gene therapies are difficult to scale to millions
“Those two techniques, CAR T and gene therapy, it's hard to think of like super scaled millions of people benefiting.”
Dave Ricks: Eli Lilly has Phase 3 siRNA drug targeting Lp(a)
“We have a project in phase three right now that knocks down the production of something called LpA, which is a lipoprotein particle that's probably thought to be about 25% of the remnant reasons why we still have cardiovascular disease and there's no medicine …”
Ricks: Eli Lilly acquired 24 companies for $3B last year
“We buy companies last year, about two dozen, which was the most of any pharma company, but actually with some of the least capital deployed. So we're making I think we spent three billion dollars on 24 companies.”
Ricks: Leaders cannot change corporate culture, only amplify positive traits
“When you're running a big ship like this, probably changing the culture is like beyond your capability. But what you can do is like extend, turn up the things that are good and turn down the things That are less good.”
Eli Lilly reduced its drug development timeline from 11 to 6.1 years
“We've moved the drug development timeline, which the industry is about nine years, from first human dose to FDA approval. And when I started, ours was about 11. And now we're 6.1.”
Ricks: Eli Lilly cut FDA submission prep time to under two weeks
“We have a submission document to get in and it used to be our standard was a 120 days from when you had the data to when you send it to the FDA. We're now doing that routinely inside of two weeks.”
Dave Ricks: Tech VCs invested $5B in AI drug discovery startups last year
“I think last year, five billion with a B went into new venture backed You know, that's what they like to call themselves. And that money is coming not so much from the traditional bio VC world, but from the tech world. Got a lot more to splash around, right?”
Dave Ricks: Fully automated 'in silico' drug discovery is a long way off
“The idea that you're going to throw on, you know, turn a switch on a computer and it's going to think about something and event, you know, the next Prozac. I don't know. I think we're a long way from that day.”
Dave Ricks: AI's primary drug discovery value is eliminating bad ideas
“It's a co-pilot model where the machine can do predictions. Probably now where we see the most value is Eliminating bad ideas that humans don't see, but in hindsight look obvious. So like, cause you can integrate a lot of multi source data and say the probabil…”